{
    "clinical_study": {
        "@rank": "8341", 
        "arm_group": [
            {
                "arm_group_label": "Cohort A", 
                "arm_group_type": "Placebo Comparator", 
                "description": "SAN-300 0.5 mg/kg subcutaneous once weekly for six weeks or placebo."
            }, 
            {
                "arm_group_label": "Cohort B", 
                "arm_group_type": "Placebo Comparator", 
                "description": "SAN-300 1.0 mg/kg subcutaneous once weekly for six weeks or placebo"
            }, 
            {
                "arm_group_label": "Cohort C", 
                "arm_group_type": "Placebo Comparator", 
                "description": "SAN-300 2.0 mg/kg subcutaneous every other week for six weeks or placebo"
            }, 
            {
                "arm_group_label": "Cohort D", 
                "arm_group_type": "Placebo Comparator", 
                "description": "SAN-300 2.0 mg/kg subcutaneous once weekly for six weeks or placebo"
            }, 
            {
                "arm_group_label": "Cohort E", 
                "arm_group_type": "Placebo Comparator", 
                "description": "SAN-300 4.0 mg/kg subcutaneous every other week for six weeks or placebo"
            }
        ], 
        "brief_summary": {
            "textblock": "A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of\n      Escalating Doses of SAN-300 in Patients with Active Rheumatoid Arthritis with Inadequate\n      Response to Disease-Modifying Anti-rheumatic Drug(s)."
        }, 
        "brief_title": "(C2013-0302) Safety and Efficacy of Escalating Doses of SAN-300 in Patients With Rheumatoid Arthritis", 
        "completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Rheumatoid Arthritis", 
        "condition_browse": {
            "mesh_term": [
                "Arthritis", 
                "Arthritis, Rheumatoid"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Diagnosed with RA for \u2265 6 months according to American College of Rheumatology\n             (ACR)/European League Against Rheumatism (EULAR) Classification Criteria 2010\n\n          2. 18 to 75 years of age, inclusive, at the time of informed consent\n\n          3. Swollen joint count of \u2265 6 (66-joint count) and tender joint count of \u2265 6 (68-joint\n             count) at Screening and randomization\n\n          4. C-reactive protein (CRP) > upper limit of normal (ULN)\n\n          5. Inadequate response to therapy or discontinuation of therapy because of unacceptable\n             toxicity from at least one prior traditional or biologic disease-modifying\n             anti-rheumatic drug (DMARD) but not more than one biologic DMARD\n\n          6. Stable dose of methotrexate (\u2265 15 mg/week and \u2264 25 mg/week) for \u2265 6 weeks before\n             randomization\n\n        Exclusion Criteria:\n\n          1. Functional Class IV as defined by ACR classification of functional status in RA\n\n          2. History of significant systemic involvement secondary to RA (e.g., vasculitis,\n             pulmonary fibrosis, or Felty's syndrome)\n\n          3. History of malignancy or carcinoma in situ within the 5 years before Screening or any\n             history of melanoma. Patients with history of excised or adequately treated\n             non-melanoma skin cancer are eligible\n\n          4. Evidence of clinically significant uncontrolled concurrent diseases such as\n             cardiovascular, endocrinologic, hematologic, hepatic, immunologic, metabolic,\n             urologic, pulmonary, neurologic, dermatologic, psychiatric, renal, and/or other major\n             diseases\n\n          5. History of recurrent clinically significant infections\n\n          6. Current active infection or serious local infection (e.g., cellulitis, abscess) or\n             systemic infection (e.g., pneumonia, septicemia) within 3 months before randomization\n\n          7. History of severe allergic or anaphylactic reactions to other biologic agents\n\n          8. History of allergies to murine protein\n\n          9. Surgery within 3 months before randomization (other than minor cosmetic surgery or\n             minor dental procedures) or plans for a surgical procedure during the Treatment\n             Period or Follow-up Period\n\n         10. History of tuberculosis or latent infection currently undergoing treatment\n\n         11. History of malaria\n\n         12. Prior treatment with more than one biologic DMARD\n\n         13. Treatment regimen with prednisone that is either over 10 mg/day (or equivalent dose\n             of another corticosteroid) or is not taken at a stable dose of \u2264 10 mg/day for at\n             least 4 weeks before randomization\n\n         14. Intra-articular corticosteroid injection(s) within 4 weeks before randomization\n\n         15. Any live immunization/vaccination, including against Herpes zoster, within 4 weeks\n             before randomization. Live vaccinations must also be avoided throughout the study\n\n         16. Abnormal laboratory value at Screening or Day -1 considered clinically significant\n\n         17. Positive for hepatitis C virus (HCV) antibody or hepatitis B surface antigen (HBsAg)\n\n         18. Positive for human immunodeficiency virus (HIV) antibody\n\n         19. History of tuberculosis or positive QuantiFERON\u00ae-TB Gold test (QFT)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "90", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 22, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02047604", 
            "org_study_id": "C2013-0302", 
            "secondary_id": "2013-003719-23"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Cohort A", 
                    "Cohort B", 
                    "Cohort C", 
                    "Cohort D", 
                    "Cohort E"
                ], 
                "intervention_name": "SAN-300", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Cohort A", 
                    "Cohort B", 
                    "Cohort C", 
                    "Cohort D", 
                    "Cohort E"
                ], 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Antirheumatic Agents"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": "Phase 2a multiple ascending dose, Anti-Very Late Antigen-1", 
        "lastchanged_date": "May 14, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Birmingham", 
                        "country": "United States", 
                        "state": "Alabama", 
                        "zip": "35216"
                    }, 
                    "name": "Santarus Clinical Investigational Site 1005"
                }, 
                "status": "Withdrawn"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "El Cajon", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "92020"
                    }, 
                    "name": "Santarus Clinical Investigational Site 1004"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Edgewater", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "32132"
                    }, 
                    "name": "Santarus Clinical Investigational Site 1002"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Palm Harbor", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "34684"
                    }, 
                    "name": "Santarus Clinical Investigational Site 1003"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Reno", 
                        "country": "United States", 
                        "state": "Nevada", 
                        "zip": "89502"
                    }, 
                    "name": "Santarus Clinical Investigational Site 1007"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Salisbury", 
                        "country": "United States", 
                        "state": "North Carolina", 
                        "zip": "28144"
                    }, 
                    "name": "Santarus Clinical Investigational Site 1006"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Middleburg Heights", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "44130"
                    }, 
                    "name": "Santarus Clinical Investigational Site 1001"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "5", 
        "official_title": "A Randomized, Double-blind, Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Escalating Doses of SAN-300 in Patients With Active Rheumatoid Arthritis With Inadequate Response to Disease-Modifying Anti-rheumatic Drug(s).", 
        "other_outcome": [
            {
                "measure": "Change in the Health Assessment Questionnaire-Disease index (HAQ-DI)", 
                "safety_issue": "No", 
                "time_frame": "End of Treatment Visit (Week 7)"
            }, 
            {
                "measure": "MRI findings of the hand and wrist", 
                "safety_issue": "No", 
                "time_frame": "End of Treatment Visit (Week 7)"
            }
        ], 
        "overall_contact": {
            "email": "betsy.smith-edwards@salix.com", 
            "last_name": "Betsy P. Smith-Edwards, RN, BSN", 
            "phone": "919 800 4980"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "Ukraine: Ministry of Health", 
                "Russia: Ministry of Health of the Russian Federation", 
                "Czech Republic: State Institute for Drug Control", 
                "Romania: National Medicines Agency"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Adverse events data are collected during a 10-week period, which includes 6 weeks of treatment and 4 weeks of follow-up.", 
            "measure": "Incidence and severity of adverse events", 
            "safety_issue": "Yes", 
            "time_frame": "10 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02047604"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Disease Activity Score (DAS) with 28-joint count using C-reactive protein", 
                "safety_issue": "No", 
                "time_frame": "Change from baseline to the End of Treatment Visit (Week 7)"
            }, 
            {
                "measure": "American College of Rheumatology 20 (ACR20) responder rate", 
                "safety_issue": "No", 
                "time_frame": "End of Treatment Visit (Week 7)"
            }
        ], 
        "source": "Salix Pharmaceuticals", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Salix Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}